Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Elisa Espinet Espinet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0690-9878; OpenAlex author ID A5047787641. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
102
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 15

  1. Regulatory elements in the Sox9 locus license the initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117176↗
  2. Molecular subtypes in pancreatic cancer: from academic promise to clinical reality. Co-author DOI 10.1186/s12943-026-02614-9↗
  3. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Co-author DOI 10.1038/s41467-024-55330-7↗
  4. Leveraging the tug-of-war with genomic retroelements to enhance immunotherapy of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-333702↗
  5. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  6. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Co-author DOI 10.1038/s41467-023-38064-w↗
  7. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  8. On the Origin of Pancreatic Cancer: Molecular Tumor Subtypes in Perspective of Exocrine Cell Plasticity. Co-author DOI 10.1016/j.jcmgh.2021.11.010↗
  9. Mechanisms of PDAC subtype heterogeneity and therapy response. Co-author DOI 10.1016/j.trecan.2022.08.005↗
  10. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Co-author DOI 10.1172/jci.insight.154475↗
  11. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
  12. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  13. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Co-author DOI 10.3390/v13061019↗
  14. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000743↗
  15. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andreas Trumpp · 8 shared papers, 2016–2025 · strength 0.89
  2. Shiv K. Singh · 5 shared papers, 2021–2025 · strength 0.71
  3. Lukas Klein · 4 shared papers, 2021–2025 · strength 0.62
  4. Gioacchino Natoli · 1 shared paper, 2025 · strength 0.54
  5. Victor Javier Sanchez-Arevalo Lobo · 2 shared papers, 2024–2026 · strength 0.50
  6. Elisabeth Heßmann · 4 shared papers, 2021–2025 · strength 0.49
  7. Volker Ellenrieder · 4 shared papers, 2021–2025 · strength 0.49
  8. Uday Kishore · 3 shared papers, 2021–2025 · strength 0.40
  9. Mengyu Tu · 3 shared papers, 2021–2025 · strength 0.40
  10. Yvan Martineau · 1 shared paper, 2026 · strength 0.36
  11. Daniela M. D'Empaire Altimari · 1 shared paper, 2026 · strength 0.36
  12. Elisa Giovannetti · 1 shared paper, 2026 · strength 0.36
  13. H. Carlo Maurer · 2 shared papers, 2022–2026 · strength 0.35
  14. Niklas Krebs · 2 shared papers, 2022–2025 · strength 0.30
  15. Argyris Papantonis · 2 shared papers, 2021–2025 · strength 0.28
  16. Laura Urbach · 2 shared papers, 2021–2025 · strength 0.28
  17. Jens Thomas Siveke · 2 shared papers, 2021–2023 · strength 0.24
  18. Marta Ballester · 1 shared paper, 2026 · strength 0.23
  19. Peter Vilmann · 1 shared paper, 2026 · strength 0.23
  20. Luís Arnes · 1 shared paper, 2026 · strength 0.23
  21. Pia Helene Klausen · 1 shared paper, 2026 · strength 0.23
  22. Albin Sandelin · 1 shared paper, 2026 · strength 0.23
  23. Ellen Puré · 1 shared paper, 2022 · strength 0.22
  24. Albrecht Neeße · 2 shared papers, 2021–2022 · strength 0.22
  25. Elyne Backx · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.